Table 2: Analysis of multiple endpoints from the MAKI trial.
P-values for the three analytical approaches based on different multiple endpoints evaluated for the MAKI trial data. λc,j=incidence of outcome j in the control arm; RRj= risk ratio for the effect of the intervention (palivizumab for RSV prophylaxis) on each outcome j, j=1,..,M.
| Description | Selected endpoints (Incidence λ and effect size RR) | Analytical approach | P-value |
|---|---|---|---|
| Three outcomes with comparable incidence and effect size | 1. Current asthma (λc,1=0.24, RR1=0.59) 2. Wheeze (λc,2=0.20, RR2=0.58) 3. Use of asthma medications (λc,3=0.13, RR3=0.71) |
minP | 0.01 |
| varP | 0.01 | ||
| bonfT | <0.01 | ||
| Three outcomes with comparable incidence and effect size, and an additional outcome with high incidence and low effect size | 1. Current asthma (λc,1=0.24, RR1=0.59) 2. Wheeze (λc,2=0.20, RR2=0.58) 3. Use of asthma medications (λc,3=0.13, RR3=0.71) 4. Nocturnal cough (λc,4=0.29, RR4=0.91) |
minP | 0.02 |
| varP | 0.03 | ||
| bonfT | <0.01 | ||
| Three outcomes with comparable incidence and effect size, and an additional outcome with low incidence and high effect size | 1. Current asthma (λc,1=0.24, RR1=0.59) 2. Wheeze (λc,2=0.20, RR2=0.58) 3. Use of asthma medications (λc,3=0.13, RR3=0.71) 4. Use of oral corticosteroids (λc,4=0.04, RR4=0.49) |
minP | 0.01 |
| varP | <0.01 | ||
| bonfT | <0.01 |